Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampIovance Biotherapeutics, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014933577249315000
Thursday, January 1, 20151239000075043000
Friday, January 1, 20162560200083749000
Sunday, January 1, 201721262000122682000
Monday, January 1, 201828430000207761000
Tuesday, January 1, 201940849000284812000
Wednesday, January 1, 202060210000317875000
Friday, January 1, 202183664000282660000
Saturday, January 1, 2022104097000451421000
Sunday, January 1, 2023106916000481871000
Loading chart...

Unlocking the unknown

SG&A Expense Trends: A Tale of Two Biotech Giants

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Iovance Biotherapeutics, Inc. and Sarepta Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Iovance's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion and investment in innovation. Meanwhile, Sarepta's expenses grew by approximately 880%, indicating a robust commitment to scaling operations and enhancing market presence. Notably, in 2023, Sarepta's SG&A expenses were nearly 4.5 times higher than Iovance's, underscoring its larger operational scale. These trends highlight the strategic financial maneuvers of these biotech leaders as they navigate the competitive landscape. As the industry evolves, monitoring such financial indicators will be key to understanding the future direction of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025